{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:02:47Z","timestamp":1773302567671,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005261","name":"CHU de Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116585","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:55:09Z","timestamp":1771433709000},"page":"116585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-5493","authenticated-orcid":false,"given":"Quentin","family":"Samaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bettuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116585_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-016-0207-3","article-title":"Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease","volume":"17","author":"Burton","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejca.2026.116585_bib2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990\u20132017: A Systematic Analysis for the Global Burden of Disease Study","volume":"5","author":"Global Burden of Disease Cancer Collaboration","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/bjd\/ljad425","article-title":"International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020","volume":"190","author":"Olsen","year":"2024","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116585_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jdv.15845","article-title":"Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns","volume":"33","author":"Amaral","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116585_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2018.01.075","article-title":"Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG","volume":"96","author":"Hillen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib6","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib7","doi-asserted-by":"crossref","first-page":"adv00637","DOI":"10.2340\/actadv.v101.751","article-title":"Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany","volume":"102","author":"Kramb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2026.116585_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18632\/oncotarget.27434","article-title":"Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study","volume":"11","author":"Montaudi\u00e9","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116585_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14978","article-title":"Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis","volume":"33","author":"Pham","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ejca.2026.116585_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116585_bib11","first-page":"JCO1903054","article-title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib12","first-page":"JCO1903357","article-title":"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib13","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1002\/cncr.34463","article-title":"A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma","volume":"128","author":"Munhoz","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib14","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.19218","article-title":"Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies","volume":"37","author":"Lang","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116585_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41416-020-01044-8","article-title":"Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)","volume":"123","author":"Hanna","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2020.07.029","article-title":"Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study","volume":"138","author":"Salzmann","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.01.048","article-title":"Real-world assessment of response to anti-PD-1 therapy in advanced cutaneous squamous cell carcinoma","author":"Shalhout","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116585_bib18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib19","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00432-022-04246-0","article-title":"Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey","volume":"149","author":"Samaran","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5694\/mja2.52199","article-title":"Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study","volume":"220","author":"McLean","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejca.2026.116585_bib21","article-title":"Real-world multicentre observational study of effectiveness and toxicity in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab","author":"Faoro","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116585_bib22","article-title":"Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol","volume":"39","author":"Verkerk","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ejca.2026.116585_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jdin.2023.06.013","article-title":"Treating locally advanced and metastatic cutaneous squamous cell carcinoma with anti-PD-1 drugs: Real-world experience in 72 patients","volume":"14","author":"Picavia","year":"2024","journal-title":"JAAD Int"},{"key":"10.1016\/j.ejca.2026.116585_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19821","article-title":"Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data","author":"Ca\u00f1ueto","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116585_bib25","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.3390\/cancers13143547","article-title":"Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group","volume":"13","author":"Hober","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116585_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1117804","article-title":"First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel","volume":"13","author":"Averbuch","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101789","article-title":"Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers","volume":"15","author":"Ksienski","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2147\/CMAR.S445910","article-title":"Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices","volume":"16","author":"Ge","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2026.116585_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/curroncol32030168","article-title":"Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study","volume":"32","author":"Haigh","year":"2025","journal-title":"Curr Oncol Tor Ont"},{"key":"10.1016\/j.ejca.2026.116585_bib30","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e19135","article-title":"Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group","volume":"38","author":"Walker","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib32","unstructured":"M\u00e9thode de la cartographie des pathologies et des d\u00e9penses de l\u2019Assurance Maladie (G11) \u3008https:\/\/www.assurance-maladie.ameli.fr\/etudes-et-donnees\/par-theme\/pathologies\/cartographie-assurance-maladie\/methode-cartographie-pathologies-depenses-assurance-maladie\u3009 (accessed November 5, 2024)."},{"key":"10.1016\/j.ejca.2026.116585_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.ejca.2026.116585_bib34","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2023.09.2274","article-title":"1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA","volume":"34","author":"Gerard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib35","article-title":"Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma","author":"Keeping","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.03.035","article-title":"Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma","volume":"170","author":"Petzold","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib37","doi-asserted-by":"crossref","first-page":"adv00693","DOI":"10.2340\/actadv.v102.2073","article-title":"Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland","volume":"102","author":"Tuominen","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2026.116585_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjd.18888","article-title":"Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real-world data from a large Italian database","volume":"183","author":"Ronconi","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116585_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1385094","article-title":"Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma","volume":"14","author":"Morecroft","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116585_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115379","article-title":"Immunotherapy followed by cetuximab in locally advanced\/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial","volume":"220","author":"Bossi","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116585_bib41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/bjd\/ljaf303","article-title":"Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial","volume":"193","author":"Becker","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116585_bib42","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3390\/biomedicines10123154","article-title":"The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy","volume":"10","author":"Jeong","year":"2022","journal-title":"Biomedicines"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:27:21Z","timestamp":1773235641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926003655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"alternative-id":["S0959804926003655"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116585","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116585"}}